Expanding a clinical trial into Asia-Pacific looks straightforward on paper. In reality, it is anything but.
Teams often approach APAC the same way they approach Europe or North America, assuming global processes will translate with minor adjustments. They don’t. The operational model that works elsewhere starts to fracture quickly, especially in China, where regulatory expectations, site dynamics, and patient access operate on an entirely different rhythm.
In a recent cross-functional discussion around an upcoming breast cancer study with heavy APAC involvement, one idea came through clearly. Local project management is not a “nice to have.” It is what holds the entire program together.
“When you have sites in China, you need a PM with China expertise in China as a regional PM,” says Hannah Urbanski. “The knowledge of the Chinese regulations and the setup in China is huge, and it changes constantly. It's difficult to keep up with the latest, what's happening if you don’t speak Mandarin. So… If you don't resource the region adequately, you will end up spinning in circles really, really quickly.”
China, and much of APAC, doesn’t behave like a scaled version of Western markets. It behaves like its own entity.
Regulatory pathways shift more frequently. Documentation expectations evolve. The way sites interact with sponsors and CROs follows different norms. If you are managing that from afar, you are always reacting a step behind. That gap shows up fast. Approval timelines slip because expectations weren’t fully understood. Communication slows down because nuance gets lost in translation. Teams spend time clarifying things that a locally embedded leader would have resolved in a single conversation.
Language is part of it, but it goes beyond that. Fluency in Mandarin is not just about translation. It’s about access. It’s about staying current, interpreting regulatory intent, and building trust with sites and authorities. Without someone on the ground who understands how things actually get done, small misalignments compound into real delays.
In many global oncology studies, China can be a primary engine for enrollment, and that impacts the entire operating model. After all, high patient volume alone does not guarantee recruitment success. What matters is how those patients are reached, how sites are activated, and how quickly issues are identified and addressed. Those levers are managed locally.
Teams often underestimate how much coordination sits behind strong recruitment numbers. Local recruitment organizations, site networks, and activation workflows all require active orchestration. Without that, even well-selected sites can underperform.
When the bulk of your patients are coming from one region, you cannot afford to manage that region remotely.
A China-based project manager is not just monitoring enrollment metrics. They are driving them. They are working directly with their team and sites, troubleshooting barriers in real time, and making adjustments before performance dips become timeline risks.
Global trials run in cycles of decisions, handoffs, and escalations. If all leadership sits in one geography, everything slows down. Meetings become harder to schedule. Decisions wait for overlapping hours. Issues linger longer than they should. A distributed leadership model fixes that, but only if it is intentional.
We have seen a simple structure work best: A global lead to steer the program, supported by regional project managers who can operate independently where it matters most. In this case, that means having dedicated leadership in both North America and China.
This strategy creates continuous operational coverage. Work does not pause when one region signs off for the day. Issues are picked up, addressed, and moved forward without waiting for the next call. A China-based PM becomes the connective tissue in that model. They translate global strategy into local execution and bring local reality back into global decision-making. That loop tightens timelines in ways centralized teams cannot replicate.
Of course, none of this replaces the need for strong global leadership. Sponsors still expect experienced oversight, especially in complex Phase 3 programs (as they should). They want confidence that someone sees the full picture, understands the interdependencies, and can keep the study on track. But global oversight without local leadership creates friction. Decisions get made without full context. Execution lags behind intent.
The better model is shared ownership. A global lead sets the direction and maintains consistency across regions. Regional PMs are empowered to execute within their markets, with the authority to act quickly and adjust when needed. In APAC, that balance is particularly important. China cannot be treated as just another node in the network. It carries enough operational weight to justify dedicated leadership with real decision-making power.
The risks associated with APAC trials are well known. Regulatory delays. Slower site activation. Recruitment variability. External factors that shift participation dynamics.
What is less discussed is how preventable many of these risks are. Take site strategy in China. Expanding the number of sites can accelerate recruitment, but it also introduces additional activation complexity. Without someone managing that trade-off locally, teams often push for expansion without fully accounting for the downstream impact on timelines.
Or consider broader geopolitical considerations. These are not theoretical risks. They influence site participation, patient flow, and study continuity. Recognizing them early requires local awareness, not retrospective analysis.
A local PM brings that forward view. They see signals earlier, understand how they will play out in practice, and adjust the approach before the risk materializes. That alone can be the difference between a study that stays on track and one that slowly drifts off schedule.
There is a tendency to treat in-country project management as a layer you add when complexity increases. In APAC, it is the opposite. It is the layer that allows everything else to function.
China, in particular, demands dedicated, in-country leadership. Not because it is more difficult, but because it operates differently. Trying to manage that difference remotely introduces challenges at every stage of the trial. The model that works best is truly simple. Strong global oversight paired with empowered regional project managers who understand their markets deeply and can act quickly.
Getting that balance right does more than reduce risk. It shortens timelines, improves recruitment performance, and creates a smoother operational experience across the board. And in a region as strategically important as APAC, that is not an advantage. It is a requirement.
Ultimately, success in APAC is not about adapting a global model at the margins. It requires building the right structure from the start, with local project management as a core component rather than an afterthought. Sponsors who get this right are not just avoiding risk, they are setting themselves up to move faster, make better decisions, and fully realize the opportunity the region offers. As more trials shift toward APAC, the question is no longer whether to invest in in-country leadership, but how quickly teams are willing to align their operating model with that reality.
If you are considering expanding your drug development program into APAC, this is the moment to get the structure right. Precision’s project management teams bring deep, on-the-ground experience across China and the broader region, with the operational clarity to anticipate challenges before they slow you down. If you want to build a model that actually holds up under APAC complexity, let’s talk.